newsfilter
← Earnings
Earnings Releases·

CervoMed — Third Quarter 2026 Earnings Summary

CervoMed reported a net loss of approximately $5.9 million for the third quarter ended September 30, 2026, with cash and equivalents totaling $19.6 million. The company advanced its neflamapimod clinical program by establishing a 100mg BID dosing regimen for dementia with Lewy bodies and receiving an Innovation Passport designation in the UK. Upcoming milestones include the presentation of 24-week biomarker data for nonfluent variant primary progressive aphasia at CTAD 2026 and the initiation of dosing for the EXPERTS-ALS trial in the first quarter of 2027.

Company
CERVOMED INC
Sector
Healthcare
Industry
Biotechnology